Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6416375 | 0.83 | TP53 (0.38) | EGFRTP53MAPTSMN1; SMN2BRAF | |
| SCHEMBL6436759 | 0.78 | KMT2A (0.43) | TP53MAPTSMN1; SMN2POLBABCG2 | |
| SCHEMBL6436750 | 0.78 | KMT2A (0.43) | TP53MAPTSMN1; SMN2POLBABCG2 | |
| SCHEMBL6415087 | 0.78 | HSPD1 (0.45) | EGFRTP53MAPTSMN1; SMN2BRAF | |
| SCHEMBL6415078 | 0.78 | HSPD1 (0.45) | EGFRTP53MAPTSMN1; SMN2BRAF | |
| SCHEMBL6432681 | 0.78 | HSPD1 (0.40) | EGFRTP53MAPTSMN1; SMN2POLB | |
| SCHEMBL6432676 | 0.78 | HSPD1 (0.40) | EGFRTP53MAPTSMN1; SMN2POLB | |
| SCHEMBL6415071 | 0.75 | MAPT (0.35) | EGFRTP53MAPTSMN1; SMN2POLB | |
| SCHEMBL6415067 | 0.75 | MAPT (0.35) | EGFRTP53MAPTSMN1; SMN2POLB | |
| SCHEMBL6416050 | 0.74 | TNF (0.38) | EGFRTP53MAPTSMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143382-A1 | Heterocyclic compounds as pharmaceutically active compounds | 4SC AG (DE) | 2005-06-30 | — | — | US | disclosed |
| WO-2005044270-A1 | OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS | 4SC AG (DE) | 2005-05-19 | — | — | WO | disclosed |
| EP-1529531-A1 | Oxadiazolopyrazine derivatives as pharmaceutically active compounds | 4SC AG (DE) | 2005-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143382-A1 | Heterocyclic compounds as pharmaceutically active compounds | NR5A2, NR1H2, NR2C2 | EGFR 1083/4885TP53 4485/4885MAPT 4420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.